{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:38:05Z","timestamp":1784806685514,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s13555-022-00741-x","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T06:02:46Z","timestamp":1653631366000},"page":"1397-1415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03051217","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yukari","family":"Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2631-8722","authenticated-orcid":false,"given":"Shinya","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"issue":"Suppl 2","key":"741_CR1","first-page":"ii18","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18\u201323 (discussion ii4\u20135).","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"741_CR2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/exd.13699","volume":"27","author":"A Boehner","year":"2018","unstructured":"Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis\u2014a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067\u201377.","journal-title":"Exp Dermatol"},{"key":"741_CR3","first-page":"93","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93\u2013104.","journal-title":"Psoriasis (Auckl)"},{"issue":"9","key":"741_CR4","first-page":"626","volume":"87","author":"N Weigle","year":"2013","unstructured":"Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626\u201333.","journal-title":"Am Fam Physician"},{"issue":"1","key":"741_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1): e006450.","journal-title":"BMJ Open"},{"key":"741_CR6","doi-asserted-by":"publisher","unstructured":"Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018;24(7).\nhttps:\/\/doi.org\/10.5070\/D3247040909.","DOI":"10.5070\/D3247040909"},{"issue":"3","key":"741_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/ijd.14671","volume":"59","author":"LA Falto-Aizpurua","year":"2020","unstructured":"Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, et al. Biological therapy for pustular psoriasis: a systematic review. Int J Dermatol. 2020;59(3):284\u201396.","journal-title":"Int J Dermatol"},{"issue":"9","key":"741_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907\u201319.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"741_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370.","journal-title":"J Dermatol"},{"issue":"4","key":"741_CR10","first-page":"535","volume":"3","author":"N Weir","year":"2006","unstructured":"Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized PEGylated Fab\u2019 fragment anti-tumor necrosis factor-\u03b1 monoclonal antibodies. Therapy. 2006;3(4):535\u201346.","journal-title":"Therapy"},{"issue":"2","key":"741_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228\u201333.","journal-title":"Ann Rheum Dis"},{"key":"741_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency. Available at https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/820110_3999437G1022_1_014_1F.pdf (in Japanese). Accessed July 2021."},{"issue":"2","key":"741_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13555-021-00494-z","volume":"11","author":"Y Umezawa","year":"2021","unstructured":"Umezawa Y, Sakurai S, Hoshii N, Nakagawa H. Certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 16-week results from a phase 2\/3 Japanese study. Dermatol Ther (Heidelb). 2021;11(2):513\u201328.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"741_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","volume":"11","author":"Y Umezawa","year":"2021","unstructured":"Umezawa Y, Asahina A, Imafuku S, et al. Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results. Dermatol Ther (Heidelb). 2021;11(3):943\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"741_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19393","author":"K Gordon","year":"2021","unstructured":"Gordon K, Warren RB, Gottlieb AB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: three-year results from two randomised Phase 3 trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021;184(4):652\u201362.","journal-title":"Br J Dermatol"},{"key":"741_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19314","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Paul C, Kerkhof PVD, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase 3, randomised, placebo-controlled studies. Br J Dermatol. 2021;184(4):640\u201351.","journal-title":"Br J Dermatol"},{"key":"741_CR17","first-page":"114","volume-title":"Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis","author":"Criteria Committee, New York Heart Association","year":"1964","unstructured":"Criteria Committee, New York Heart Association. Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6th ed. Boston: Little, Brown and Co; 1964. p. 114.","edition":"6"},{"issue":"7","key":"741_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"741_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","volume":"89","author":"A Onoufriadis","year":"2011","unstructured":"Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432\u20137.","journal-title":"Am J Hum Genet"},{"issue":"26","key":"741_CR20","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340.","journal-title":"N Engl J Med"},{"issue":"11","key":"741_CR21","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","volume":"76","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, F\u00f6rger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890\u20136.","journal-title":"Ann Rheum Dis"},{"key":"741_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/IJWH.S125784","volume":"10","author":"MK Trivedi","year":"2018","unstructured":"Trivedi MK, Vaughn AR, Murase JE. Pustular psoriasis of pregnancy: current perspectives. Int J Womens Health. 2018;10:109\u201315.","journal-title":"Int J Womens Health"},{"key":"741_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jdin.2022.03.009","volume":"7","author":"CB Johansen","year":"2022","unstructured":"Johansen CB, Egeberg A, Jimenez-Solem E, Skov L, Thomsen SF. Psoriasis and adverse pregnancy outcomes: a nationwide case-control study in 491,274 women in Denmark. JAAD Int. 2022;7:146\u201355.","journal-title":"JAAD Int"},{"issue":"12","key":"741_CR24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/1346-8138.14664","volume":"45","author":"A Morita","year":"2018","unstructured":"Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45(12):1371\u201380.","journal-title":"J Dermatol"},{"issue":"4","key":"741_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362.","journal-title":"J Dermatol"},{"issue":"2","key":"741_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jdv.15287","volume":"33","author":"Y Okubo","year":"2019","unstructured":"Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33(2):325\u201332.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"741_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529\u201339.","journal-title":"J Dermatol"},{"issue":"6","key":"741_CR28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.12773","volume":"29","author":"H Saeki","year":"2015","unstructured":"Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"741_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000942","volume":"5","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5(1): e000942.","journal-title":"RMD Open"},{"issue":"2","key":"741_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","volume":"66","author":"K Gordon","year":"2012","unstructured":"Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"9494","key":"741_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367\u201374.","journal-title":"Lancet"},{"issue":"6","key":"741_CR32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archderm.143.6.719","volume":"143","author":"S Tyring","year":"2007","unstructured":"Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719\u201326.","journal-title":"Arch Dermatol"},{"issue":"9","key":"741_CR33","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011\u20137.","journal-title":"J Dermatol"},{"issue":"3","key":"741_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741\u201351.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00741-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T03:47:15Z","timestamp":1655783235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00741-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00741-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}